Kinetic Concepts (NYSE:KCI) has received FDA 510[k] clearance for its LifeCell Tissue Matrix. The matrix is used to treat chronic, trauma, surgical and other acute wounds. The product utilizes the company’s Strattice technology, a sterile reconstructive tissue matrix that supports tissue regeneration.
Strattice is derived from pig skin (or porcine dermis, as the company likes to say) and treated with a process to remove cells, significantly reducing the likelihood of rejection. Strattice acts as a scaffold, which is revascularized and repopulated with host cells. Ultimately, the one time pig skin is converting into functional, living tissue.
The product can be used to manage a wide range of wound types, including pressure ulcers, diabetic ulcers and wounds stemming from trauma or surgery. Today’s announcement marks the fourth FDA clearance received for Strattice, which is also recommended for soft tissue reinforcement, including hernia repair and breast reconstruction.
The clearance builds upon LifeCell’s significant product portfolio. The company launched in 1994 with AlloDerm, a graft for burn patients. That product has been used in more than one million grafts and implants.
KCI acquired LifeCell in April 2008 for $1.7 billion in cash. The company borrowed over $1 billion from Bank of America (NYSE:BAC) to finance the deal. The acquisition has done little to inspire investor confidence. With stock trading near $20, down from a high of $65 last October, KCI has had an abysmal year.
click to enlarge